GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent
GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006355/en/
GE HealthCare is innovating in contrast media (Photo: Business Wire)
The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relaxivity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs). Unlike gadolinium, manganese is endogenous, meaning that it is a trace element that is naturally occurring in and efficiently eliminated from the body. Along with its magnetic properties, this makes a manganese-based agent a viable alternative to gadolinium. In addition, a non-gadolinium agent could help limit the potential impact of post-patient excreted gadolinium in the environment.
The clinical trial, based at the clinical research unit at the Oslo University Hospital, Rikshospitalet, Norway, and overseen by Lead Investigator, Hasse K. Zaré, aims to investigate the safety profile and how this injectable manganese contrast agent is eliminated from the body in healthy volunteers. Previous manganese-based MRI agents have been reliant on a ‘free manganese’ release mechanism for their imaging efficacy. This novel investigational agent is tightly bound to the chelate, in a macrocyclic cage-like structure, so it is rapidly eliminated from - rather than actively released into - the body.
Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics unit, said: “For many years we’ve been committed to investing in, and bringing to market, products to help solve some of radiology’s biggest challenges and unmet needs. This manganese-based MRI agent is one of a number of novel agents we have at various stages of development in our innovation pipeline, all of which aim to give practitioners more choice in delivering precision care for their patients.”
GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006355/en/
GE HealthCare Media:
M +3364 700 8271
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World’s Major Economies Playing Catch-Up as Widespread Adoption Drives Global Real-Time Payments Growth – ACI Worldwide Report29.3.2023 03:30:00 CEST | Press release
New sophisticated use cases for consumers and businesses are driving global RTP volumes to record highs, with 195.0B RTP transactions recorded globally in 2022 — a YoY growth of 63.2% — according to the 2023 Prime Time for Real-Time report, published by ACI Worldwide (NASDAQ: ACIW), a global leader in mission-critical, real-time payments software, in partnership with GlobalData, a leading data and analytics company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005314/en/ Prime Time for Real-Time 2023 : Key Facts and Figures at a Glance (Graphic: Business Wire) 511.7B real-time transactions globally are forecast by 2027, representing a 2022-2027 compound annual growth rate (CAGR) of 21.3%. By 2027, RTPs are expected to account for 27.8% of all electronic payments globally. India remains the undisputed RTP leader, with a staggering 89.5B transactions in 2022 and a YoY growth rate of 76.8%. India accounted for 46% of al
AGCO’s 2022 Sustainability Report Shows Solid Progress28.3.2023 19:00:00 CEST | Press release
AGCO (NYSE: AGCO), a worldwide manufacturer and distributor of agricultural equipment, infrastructure and precision ag technology, today released its 2022 Sustainability Report. The report showcases AGCO’s progress on environmental, social and governance issues as it strives to deliver farmer-focused solutions to sustainably feed our world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005749/en/ AGCO is delivering on its sustainability commitments, from industry-leading innovation to improve sustainability outcomes for farmers, to decarbonizing our products and operations, to offering our talented, diverse employees a safer, more engaging workplace. (Photo: Business Wire) “AGCO is delivering on its sustainability commitments, from industry-leading innovation to improve sustainability outcomes for farmers, to decarbonizing our products and operations, to offering our talented, diverse employees a safer, more engaging
Lunaphore Expands Its COMET™ Portfolio to Become the First Universal, End-to-end Spatial Biology Solution28.3.2023 17:00:00 CEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the launch of a full expansion of its product offering to provide a universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research. This milestone marks the launch of the enhanced version of the company’s revolutionary COMET™ platform and its comprehensive product suite, which includes a wide range of tools and applications across all research and drug development stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005685/en/ Lunaphore's universal, end-to-end spatial biology solution portfolio. (Photo: Lunaphore) Lunaphore’s multiplex immunofluorescence (mIF) solution portfolio now includes the latest version of the hyperplex, high-throughput, fully automated COMET™ instrument, providing un
Yokohama Business Events Website Redesign: Discover Yokohama in the Here and Now With Technical-Visits* and New Videos!28.3.2023 17:00:00 CEST | Press release
The Yokohama Convention & Visitors Bureau (YCVB) website is an important point of contact for convention organizers and incentive-travel planners in Japan and around the world. Today, we are announcing that our website has been completely redesigned and now offers new and exclusive experiences for business events—experiences that can be had only in the city of Yokohama. On our new website, organizers can find convenient ways to add value to their conferences and attract more participants as people return to in-person events. Yokohama is a global leader in international conferences with numerous event facilities, excellent accommodations, and tourist attractions conveniently located within the Yokohama bay area. Given the growing demand for close interaction with local communities and the many different types of business events, we have created a new web page featuring technical-visit programs and have given sustainability a larger place in our content. Additionally, compelling videos o
Exclusively for Business Event Participants: Sustainable experiences available only in Yokohama28.3.2023 17:00:00 CEST | Press release
Now, more than ever, a sustainable approach is essential for successful international conferences and events. At Yokohama Convention & Visitors Bureau (YCVB), we value sustainability in all our activities and do our utmost to contribute to a greener, more inclusive, and culturally diverse world. We have therefore created four amazing sustainable experiences, which are exclusively for business event participants, and unique to the city of Yokohama. Yokohama Mobile Yoga Experience yoga anytime and anywhere in the vibrant metropolis of Yokohama. This wellness activity can be held anywhere—parks, conference rooms, or exhibition halls. Inspired by Yokohama’s natural beauty, the yoga sessions use the calming sound of waves, delicate aromas, and images of Yokohama’s beautiful sea to create a relaxing and meditative experience for business event participants. To ensure accessibility to all, the sessions can be arranged for any level of experience, can be held in Japanese and English, and don’t